MetaCap

Novavax (NVAX) vs Windward Bio Group (WWB)

Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.

Summary

Windward Bio Group is the larger company by market cap ($1.45 billion vs $1.23 billion), about 1.2 times the size.

Summary generated from market data by MetaCap's automated system. Methodology

Relative performance

NVAX-12.43%WWB-14.79%
+7%-8%-22%
Nov 13, 20261 yearNov 20, 2026
NVAX-12.43%WWB-14.79%
+1%-7%-16%
Nov 9, 20265 yearsNov 16, 2026

Percent change in share price from the first common trading day shown; excludes dividends.

Head-to-head

NVAX versus WWB key metrics
MetricNVAXWWB
Share price$7.47$24.29
Market cap$1.23B$1.45B
1-day change-3.24%+1.15%
YTD return+11.16%—
1-year return+15.46%—
5-year return-96.57%—
EPS (TTM)$-0.52$-1.18
Dividend yield0.00%0.00%
Annual dividend$0.00$0.00
Revenue (latest FY)$1.12B—
Revenue growth (YoY)+64.69%—
Net income (latest FY)$440.30M—
Gross margin93.50%—
Operating margin40.30%—
Net margin39.19%—
52-week high$13.39$33.99
52-week low$6.36$18.35
Distance from 52-week high-44.21%-28.55%
Analyst consensusbuy—
Avg. price target upside+88.89%—
Average volume6.67M434.33K
Shares outstanding165.01M59.58M
Employees74933
SectorHealth CareHealth Care
IndustryBiotechnology: Biological Products (No Diagnostic Substances)Biotechnology: Biological Products (No Diagnostic Substances)

Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.

About Novavax

NVAX stock →

Novavax, Inc., a biotechnology company, engages in the discovery, development, and commercialization of vaccines to prevent serious infectious diseases in the United States, Europe, and internationally. The company commercializes Nuvaxovid, a COVID-19 vaccine; and R21 Matrix-M adjuvant malaria vaccine.

Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 749 employees

About Windward Bio Group

WWB stock →

Windward Bio Group AG operates as a clinical stage biotechnology company that develops ultra-long-acting antibody medicines for patients with respiratory and dermatologic diseases. Its drug candidates WIN378, an ultra-long-acting and novel fully human monoclonal antibody, which has completed Phase I clinical study that inhibits thymic stromal lymphopoietin (TSLP); and WIN027, an ultra-long-acting bispecific antibody that is in Phase I clinical study simultaneously targets TSLP and interleukin-13 (IL-13) and two clinically validated drivers of inflammatory disease.

Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 33 employees

NVAX vs WWB FAQ

Which is bigger, Novavax or Windward Bio Group?

Windward Bio Group (WWB) is larger, with a market capitalization of $1.45B compared with $1.23B for Novavax (NVAX).

Are Novavax and Windward Bio Group in the same industry?

Yes. Both are classified in the Biotechnology: Biological Products (No Diagnostic Substances) industry within the Health Care sector.

More comparisons